BRPI1014545A2 - composição farmacêutica para prevenção e/ou tratamento de transtorno de déficit de atenção/hiperatividade - Google Patents

composição farmacêutica para prevenção e/ou tratamento de transtorno de déficit de atenção/hiperatividade

Info

Publication number
BRPI1014545A2
BRPI1014545A2 BRPI1014545A BRPI1014545A BRPI1014545A2 BR PI1014545 A2 BRPI1014545 A2 BR PI1014545A2 BR PI1014545 A BRPI1014545 A BR PI1014545A BR PI1014545 A BRPI1014545 A BR PI1014545A BR PI1014545 A2 BRPI1014545 A2 BR PI1014545A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
pharmaceutical composition
attention deficit
hyperactivity disorder
Prior art date
Application number
BRPI1014545A
Other languages
English (en)
Inventor
Shinji Takahashi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BRPI1014545A2 publication Critical patent/BRPI1014545A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1014545A 2009-05-29 2010-05-28 composição farmacêutica para prevenção e/ou tratamento de transtorno de déficit de atenção/hiperatividade BRPI1014545A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009129780 2009-05-29
PCT/JP2010/059085 WO2010137689A1 (ja) 2009-05-29 2010-05-28 注意欠陥／多動性障害新規予防用及び／又は治療用医薬組成物

Publications (1)

Publication Number Publication Date
BRPI1014545A2 true BRPI1014545A2 (pt) 2016-04-05

Family

ID=43222794

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014545A BRPI1014545A2 (pt) 2009-05-29 2010-05-28 composição farmacêutica para prevenção e/ou tratamento de transtorno de déficit de atenção/hiperatividade

Country Status (9)

Country Link
US (1) US20120088772A1 (pt)
EP (1) EP2436396A4 (pt)
JP (1) JPWO2010137689A1 (pt)
KR (1) KR20120036813A (pt)
CN (1) CN102448495A (pt)
BR (1) BRPI1014545A2 (pt)
CA (1) CA2762528A1 (pt)
MX (1) MX2011012743A (pt)
WO (1) WO2010137689A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103351348A (zh) * 2013-07-15 2013-10-16 黄河三角洲京博化工研究院有限公司 一种2-甲胺基嘧啶盐酸盐的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1982799A (en) 1998-01-23 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel potassium channel protein
AU5487199A (en) * 1998-08-14 2000-03-06 Elan Pharmaceuticals, Inc. Novel esk potassium channel polypeptide and polynucleotide compositions
US20020132793A1 (en) * 2000-08-28 2002-09-19 Mel Epstein Use of methylphenidate compounds to enhance memory
US6759427B2 (en) * 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
CA2465337A1 (en) 2001-11-14 2003-05-22 Yamanouchi Pharmaceutical Co., Ltd. Transgenic animal
PT1479397E (pt) * 2002-02-05 2011-09-01 Astellas Pharma Inc Derivados de 2,4,6-triamino-1,3,5-triazina
CA2694887A1 (en) * 2007-08-01 2009-02-05 Henriette Husum Bak-Jensen Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Also Published As

Publication number Publication date
KR20120036813A (ko) 2012-04-18
US20120088772A1 (en) 2012-04-12
JPWO2010137689A1 (ja) 2012-11-15
EP2436396A1 (en) 2012-04-04
EP2436396A4 (en) 2012-10-31
MX2011012743A (es) 2012-04-20
CA2762528A1 (en) 2010-12-02
WO2010137689A1 (ja) 2010-12-02
CN102448495A (zh) 2012-05-09

Similar Documents

Publication Publication Date Title
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BR112014002619A2 (pt) composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
DK2532366T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
BR112013024401A2 (pt) métodos e composições para o tratamento do transtorno do déficit de atenção
DK2532680T3 (da) Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
BR112013016535A2 (pt) extratos vegetais para o tratamento e prevenção de infecções
DK2818481T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
PL2532743T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
BRPI1009920A2 (pt) composições bacterianas para profilaxina e tratamento de doença degenerativa.
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
BR112012010670A2 (pt) métodos para tratamento de distúrbio de défict de atenção/hiperatividade
EP2818482A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2824114A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI1008566A8 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BRPI1015472A2 (pt) métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
BRPI1010517A2 (pt) métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
BRPI0811870A2 (pt) Tratamento e prevenção de influenza
BRPI0916043A2 (pt) composição farmacêutica e alimento funcional para prevenir ou tratar câncer
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BR112014009456A2 (pt) uso de melatonina para o tratamento e/ou prevenção de mucosite

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2368 DE 24-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.